Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Interest Income
Income earned on cash, deposits, and investments held by the company.
Aura Biosciences, Inc.NASDAQ: AURA
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $1.19M fell 25.3% year over year, in line with the -25.3% change in trailing-twelve-month interest income. Sequentially, it fell 22.9% from the prior quarter. Over 3 fiscal years it compounded at +52.7% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -25.3% toward the trailing-twelve-month pace of -25.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 6.63M USD
- Year-over-year change
- -29.7%
- 4-year CAGR
- +375.2%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.63M | -29.7% |
| FY2024 | 2024-12-31 | 9.43M | +9.8% |
| FY2023 | 2023-12-31 | 8.59M | +360.7% |
| FY2022 | 2022-12-31 | 1.86M | +14238.5% |
| FY2021 | 2021-12-31 | 13K | — |
Interest Income vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.3% is the 6th highest of 11, against a peer median of -21.9%.
- Over three fiscal years its annual growth of +52.7% compares with a peer median of +73.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $24.93M USD | -32.8% | +70.4% | 39.3% | |
| LTM Sep 2026 | $18.04M USD | +57.2% | +1228.3% | — | |
| FY2025 | $11.01M USD | +35.9% | +88.4% | 169.4% | |
| LTM Mar 2026 | $10.45M USD | -28.9% | +76.7% | 137.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $6.77M USD | +97.1% | +37.5% | — |
| LTM Mar 2026 | $6.23M USD | -25.3% | +52.7% | — | |
| LTM Mar 2026 | $5.93M USD | -29.4% | +26.0% | 3.8% | |
| LTM Mar 2026 | $5.25M USD | -28.4% | — | — | |
| LTM Mar 2026 | CHF 1.76M CHF | -15.4% | +137.6% | 349.0% | |
| LTM Mar 2026 | $483K USD | -3.4% | -13.0% | 10.8% | |
| LTM Mar 2026 | $3 USD | -100.0% | — | 0.0% | |
| Peer median (excluding AURA) | — | -21.9% | +73.5% | 39.3% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.3M | 0 | 0 |
| Gross Profit | 0 | 0 | (1.3M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.16M | 42.24M | 63.94M | 73.3M | 90.3M |
| Selling, General & Admin | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M |
| Operating Expenses | 35.25M | 60.3M | 83.7M | 96.12M | 112.79M |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| EBITDA | (34.41M) | (57.59M) | (74.98M) | (85.58M) | (104.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.25M) | (60.3M) | (84.99M) | (96.12M) | (112.79M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 1.86M | 8.59M | 9.43M | 6.63M |
| Interest Expense | 13K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 1.53M | 8.72M | 9.31M | 6.71M |
| Income Before Tax | (35.25M) | (58.76M) | (76.27M) | (86.81M) | (106.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 137K | 112K | 108K |
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| EPS (Diluted) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| Weighted Avg Shares | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
| Weighted Avg Shares (Diluted) | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.